NCT01089569View on ClinicalTrials.gov

Continuous Glucose Monitoring Evaluation of Exenatide Twice Daily Versus Insulin Glargine

NACompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

April 30, 2010

Primary Completion Date

May 31, 2013

Study Completion Date

May 31, 2013

Conditions
Type 2 Diabetes
Interventions
DRUG

Exenatide

5 mcg BID (twice daily) for 1 month increasing to 10 mcg BID for the remainder of the study

DRUG

Insulin Glargine

.1 unit per kg to start, titrated based on Continuous Glucose Monitoring results

Trial Locations (1)

55416

International Diabetes Center, Minneapolis

Sponsors

Collaborators (1)

Sanofi
All Listed Sponsors
collaborator

International Diabetes Center at Park Nicollet

OTHER

collaborator

Sanofi

INDUSTRY

lead

HealthPartners Institute

OTHER

NCT01089569 - Continuous Glucose Monitoring Evaluation of Exenatide Twice Daily Versus Insulin Glargine | Biotech Hunter | Biotech Hunter